His Story So Far…
As a life-long clinician-scientist exposed to high level research from an early age in his career, Jean-Francois Geschwind, MD has always been fascinated by the integration of basic biology into clinical medicine. It is because of his passion, enthusiasm and creativity that he has made such a considerable contribution to the field of liver cancer both in terms of basic, translational and clinical research as well as therapeutic developments.
Jeff Geschwind is originally from France. He earned his medical degree from Boston University School of Medicine (BUSM) and completed his residency training in diagnostic radiology at the University of California at San Francisco (UCSF) as a Resident-Scholar sponsored by the National Institutes of Health (NIH) which allowed him to dedicate a year of his residency to basic research. During that year of research, he worked under the guidance and mentorship of Dr. Charles Higgins focusing on cardiac magnetic resonance imaging, published many scientific manuscripts, earned his first award and more importantly learned how to manage and run a research laboratory. He then pursued his fellowship training in vascular and interventional radiology at the Johns Hopkins University School of Medicine before joining the faculty as an Assistant Professor. Shortly after, he was appointed the Director of the Division of Vascular and Interventional Radiology and then a few years later, he was promoted to Professor of Radiology, Surgery, and Oncology at the Johns Hopkins University School of Medicine. In this leadership role, he oversaw a massive growth in the division, both in terms of clinical activities and research.
As a physician, he concentrated his efforts on treating hepatic cancer and more generally focused on the nascent field of interventional oncology, which he helped develop into a major new field of medicine. He founded the Center of Oncologic Interventions, which utilized revolutionary imaging technology in collaboration with Philips Health Care and partly supported by funding from the NIH to visualize tumors, target them with exquisite precision and treat them more effectively. Finally, after 19 years at Johns Hopkins, Dr. Geschwind was recruited to Yale School of Medicine to become the new Chairman of Radiology and Biomedical Imaging, Radiologist in Chief at Yale-New Haven Hospital and Professor of Radiology and Medicine (Oncology). While there, he created a new research laboratory dedicated to interventional oncology and received a major grant from the NIH for research on targeting and imaging of the tumor microenvironment.
Jeff Geschwind was a member of several medical organizations, including among others the American Society of Clinical Oncology, the Hepatobiliary Task Force of the National Cancer Institute, the Radiological Society of North America, the American Association for Cancer Research, the International Liver Cancer Association and remain an active member of the Society of Interventional Radiology and the Cardiovascular and Interventional Radiology Society of Europe. Dr. Geschwind is a Diplomate of the American Board of Radiology. He received many awards throughout his career, the latest being the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who’s Who.
Jeff has authored or co-authored hundreds of scientific articles mostly related to liver cancer and interventional oncology, the newest and fastest growing branch of interventional radiology. His H-index as assessed by Mendeley, a subsidiary of Elsevier designed to assess the impact of scientific publications, is 56 which is one of the highest in the field of Interventional Radiology and Radiology/Imaging Sciences. He has edited or co-edited several books about interventional radiology and oncology, including what is considered to be the textbook of reference for the field of Interventional Radiology. Dr. Geschwind is the first person to be excited about new technology or therapies that can
transform existing cancer care.
This is what led Dr. Geschwind to create a new company while he was on faculty at Johns Hopkins and bring this new promising drug therapy to the clinic so that cancer patients can benefit from his breakthrough research. He is currently the Director of Oncology at USA Vein Clinics and USA Fibroid and Vascular Centers where his goal is to develop centers where cancer patients can be treated with cutting edge minimally invasive image-guided procedures on an outpatient basis.
- The Hepatobiliary Task Force of the National Cancer
- The American Society of Clinical Oncology
- The Radiological Society of North America
- The American Association for Cancer Research
- The International Liver Cancer Association
- The Cardiovascular and Interventional Radiology Society of Europe
Jeff Geschwind received his medical degree from Boston University School of Medicine (BUSM). Founded in 1848, the medical school was the first institution in the world to formally educate female physicians, and it continues in that same sense of cutting-edge professionalism to this day.